301 related articles for article (PubMed ID: 17920108)
1. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
Carey MS; Bacon M; Tu D; Butler L; Bezjak A; Stuart GC
Gynecol Oncol; 2008 Jan; 108(1):100-5. PubMed ID: 17920108
[TBL] [Abstract][Full Text] [Related]
2. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
Bezjak A; Tu D; Bacon M; Osoba D; Zee B; Stuart G; Roy JA; Piccart M; Eisenhauer E
J Clin Oncol; 2004 Nov; 22(22):4595-603. PubMed ID: 15466785
[TBL] [Abstract][Full Text] [Related]
3. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
4. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in ovarian cancer patients receiving chemotherapy.
Lakusta CM; Atkinson MJ; Robinson JW; Nation J; Taenzer PA; Campo MG
Gynecol Oncol; 2001 Jun; 81(3):490-5. PubMed ID: 11371144
[TBL] [Abstract][Full Text] [Related]
6. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
7. Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study.
McQuellon RP; Thaler HT; Cella D; Moore DH
Gynecol Oncol; 2006 May; 101(2):296-304. PubMed ID: 16376417
[TBL] [Abstract][Full Text] [Related]
8. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial.
Butler L; Bacon M; Carey M; Zee B; Tu D; Bezjak A
J Clin Oncol; 2004 Jun; 22(12):2461-8. PubMed ID: 15197209
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma.
Gadducci A; Viacava P; Cosio S; Fanelli G; Fanucchi A; Cecchetti D; Cristofani R; Genazzani AR
Anticancer Res; 2003; 23(1B):549-56. PubMed ID: 12680144
[TBL] [Abstract][Full Text] [Related]
10. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E
Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805
[TBL] [Abstract][Full Text] [Related]
11. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
Zhao XD; Zhang Y; He SR; Yang L
Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810
[TBL] [Abstract][Full Text] [Related]
12. Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.
Efficace F; Biganzoli L; Piccart M; Coens C; Van Steen K; Cufer T; Coleman RE; Calvert HA; Gamucci T; Twelves C; Fargeot P; Bottomley A;
Eur J Cancer; 2004 May; 40(7):1021-30. PubMed ID: 15093577
[TBL] [Abstract][Full Text] [Related]
13. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer.
Brown J; Thorpe H; Napp V; Fairlamb DJ; Gower NH; Milroy R; Parmar MK; Rudd RM; Spiro SG; Stephens RJ; Waller D; West P; Peake MD
J Clin Oncol; 2005 Oct; 23(30):7417-27. PubMed ID: 16157935
[TBL] [Abstract][Full Text] [Related]
14. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
Markman M; Federico M; Liu PY; Hannigan E; Alberts D
Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
[TBL] [Abstract][Full Text] [Related]
15. Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy.
Fang FM; Liu YT; Tang Y; Wang CJ; Ko SF
Cancer; 2004 Jan; 100(2):425-32. PubMed ID: 14716781
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study.
Efficace F; Therasse P; Piccart MJ; Coens C; van Steen K; Welnicka-Jaskiewicz M; Cufer T; Dyczka J; Lichinitser M; Shepherd L; de Haes H; Sprangers MA; Bottomley A
J Clin Oncol; 2004 Aug; 22(16):3381-8. PubMed ID: 15310784
[TBL] [Abstract][Full Text] [Related]
17. Quality of life as a survival predictor for esophageal squamous cell carcinoma treated with radiotherapy.
Fang FM; Tsai WL; Chiu HC; Kuo WR; Hsiung CY
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1394-404. PubMed ID: 15050315
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study.
Stiff PJ; Shpall EJ; Liu PY; Wilczynski SP; Callander NS; Scudder SA; Jazieh AR; Samlowski W; McCoy J; Alberts DS;
Gynecol Oncol; 2004 Jul; 94(1):98-106. PubMed ID: 15262126
[TBL] [Abstract][Full Text] [Related]
19. [Quality of life in patients with advanced ovarian cancer who underwent cytoreductive surgery followed by chemotherapy].
Tei S; Kigawa J; Okada M; Itamochi H; Kanamori Y; Irie T; Minagawa Y; Terakawa N
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Oct; 48(10):883-7. PubMed ID: 8921520
[TBL] [Abstract][Full Text] [Related]
20. Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment.
Le T; Leis A; Pahwa P; Wright K; Ali K; Reeder B; Hopkins L; Fung MF
Gynecol Oncol; 2004 Mar; 92(3):839-44. PubMed ID: 14984950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
